25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

HRTIS (Herantis) Stock Analysis
Buy, Hold or Sell?

Let's analyze Herantis together

I guess you are interested in Herantis Pharma Oyj. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Herantis’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Herantis’s Price Targets

I'm going to help you getting a better view of Herantis Pharma Oyj. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Herantis Pharma Oyj

I send you an email if I find something interesting about Herantis Pharma Oyj.

1. Quick Overview

1.1. Quick analysis of Herantis (30 sec.)










1.2. What can you expect buying and holding a share of Herantis? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€-0.01
Expected worth in 1 year
€-0.84
How sure are you?
40.0%

+ What do you gain per year?

Total Gains per Share
€-0.82
Return On Investment
-51.9%

For what price can you sell your share?

Current Price per Share
€1.59
Expected price per share
€1.45 - €1.75
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Herantis (5 min.)




Live pricePrice per Share (EOD)
€1.59
Intrinsic Value Per Share
€-2.69 - €-0.07
Total Value Per Share
€-2.70 - €-0.08

2.2. Growth of Herantis (5 min.)




Is Herantis growing?

Current yearPrevious yearGrowGrow %
How rich?-$283.6k$5.5m-$5.8m-2,045.0%

How much money is Herantis making?

Current yearPrevious yearGrowGrow %
Making money-$5.7m$326.6k-$6m-105.7%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Herantis (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#759 / 872

Most Revenue
#720 / 872

Most Profit
#441 / 872

Most Efficient
#311 / 872
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Herantis?

Welcome investor! Herantis's management wants to use your money to grow the business. In return you get a share of Herantis.

First you should know what it really means to hold a share of Herantis. And how you can make/lose money.

Speculation

The Price per Share of Herantis is €1.59. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Herantis.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Herantis, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €-0.01. Based on the TTM, the Book Value Change Per Share is €-0.21 per quarter. Based on the YOY, the Book Value Change Per Share is €0.20 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Herantis.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 β‚¬% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share
Usd Eps-0.24-15.1%-0.24-15.1%0.010.9%-0.23-14.2%-0.35-21.9%-0.34-21.6%
Usd Book Value Change Per Share-0.24-15.1%-0.24-15.1%0.2314.6%-0.01-0.8%-0.02-1.3%-0.11-6.7%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.24-15.1%-0.24-15.1%0.2314.6%-0.01-0.8%-0.02-1.3%-0.11-6.7%
Usd Price Per Share1.77-1.77-1.84-1.84-2.56-3.79-
Price to Earnings Ratio-7.39--7.39-135.61-41.32-21.85--1.64-
Price-to-Total Gains Ratio-7.35--7.35-7.93--21.37--11.07-3.87-
Price to Book Ratio-150.22--150.22-8.03--267.23--137.99--192.98-
Price-to-Total Gains Ratio-7.35--7.35-7.93--21.37--11.07-3.87-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.856166
Number of shares538
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.24-0.02
Usd Total Gains Per Share-0.24-0.02
Gains per Quarter (538 shares)-129.53-10.92
Gains per Year (538 shares)-518.13-43.67
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-518-5280-44-54
20-1036-10460-87-98
30-1554-15640-131-142
40-2073-20820-175-186
50-2591-26000-218-230
60-3109-31180-262-274
70-3627-36360-306-318
80-4145-41540-349-362
90-4663-46720-393-406
100-5181-51900-437-450

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%1.02.00.033.3%1.04.00.020.0%1.09.00.010.0%1.012.00.07.7%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%4.06.00.040.0%6.07.00.046.2%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.013.00.0%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%4.06.00.040.0%6.07.00.046.2%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Herantis Pharma Oyj compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.206-0.2060%0.199-204%-0.011-95%-0.017-92%-0.091-56%
Book Value Per Share---0.010-0.0100%0.196-105%0.061-116%0.104-110%0.108-109%
Current Ratio--4.0554.0550%3.391+20%3.574+13%3.794+7%4.254-5%
Debt To Asset Ratio--1.0951.0950%0.299+266%0.801+37%0.772+42%0.777+41%
Debt To Equity Ratio----0%0.427-100%0.142-100%2.614-100%2.671-100%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--33689622.00033689622.0000%42418303.000-21%38520923.333-13%54080950.498-38%77014009.197-56%
Eps---0.205-0.2050%0.012-1865%-0.193-6%-0.298+45%-0.294+43%
Free Cash Flow Per Share---0.272-0.2720%-0.192-29%-0.278+2%-0.321+18%-0.255-6%
Free Cash Flow To Equity Per Share---0.272-0.2720%-0.006-98%-0.098-64%-0.055-80%-0.046-83%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---0.070----------
Intrinsic Value_10Y_min---2.693----------
Intrinsic Value_1Y_max---0.202----------
Intrinsic Value_1Y_min---0.311----------
Intrinsic Value_3Y_max---0.458----------
Intrinsic Value_3Y_min---0.904----------
Intrinsic Value_5Y_max---0.535----------
Intrinsic Value_5Y_min---1.460----------
Market Cap38310732.000+5%36503622.00036503622.0000%37949310.000-4%38069784.000-4%52861581.720-31%78174614.808-53%
Net Profit Margin----0%-0%-0%-0%-838.1940%
Operating Margin----0%-0%-0%-0%-833.5590%
Operating Ratio----0%-0%-0%-0%1420.965-100%
Pb Ratio-157.657-5%-150.221-150.2210%8.029-1971%-267.229+78%-137.987-8%-192.977+28%
Pe Ratio-7.755-5%-7.389-7.3890%135.611-105%41.319-118%21.852-134%-1.637-78%
Price Per Share1.590+5%1.5151.5150%1.575-4%1.580-4%2.194-31%3.244-53%
Price To Free Cash Flow Ratio-5.853-5%-5.577-5.5770%-8.186+47%-6.069+9%-6.971+25%-17.071+206%
Price To Total Gains Ratio-7.709-5%-7.346-7.3460%7.928-193%-21.368+191%-11.069+51%3.868-290%
Quick Ratio--2.3662.3660%3.757-37%3.258-27%3.771-37%5.952-60%
Return On Assets---1.921-1.9210%0.041-4732%-1.125-41%-1.468-24%-1.041-46%
Return On Equity----0%0.059-100%0.020-100%-8.7360%-5.4020%
Total Gains Per Share---0.206-0.2060%0.199-204%-0.011-95%-0.017-92%-0.091-56%
Usd Book Value---283678.200-283678.2000%5517545.660-105%1721164.362-116%2933610.947-110%3034204.227-109%
Usd Book Value Change Per Share---0.241-0.2410%0.232-204%-0.013-95%-0.020-92%-0.106-56%
Usd Book Value Per Share---0.012-0.0120%0.229-105%0.071-116%0.122-110%0.126-109%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--39329264.72339329264.7230%49519126.922-21%44969325.899-13%63134101.611-38%89906154.337-56%
Usd Eps---0.239-0.2390%0.014-1865%-0.226-6%-0.348+45%-0.343+43%
Usd Free Cash Flow---7640633.000-7640633.0000%-5412073.404-29%-7831276.814+2%-9016817.120+18%-7163001.096-6%
Usd Free Cash Flow Per Share---0.317-0.3170%-0.225-29%-0.325+2%-0.374+18%-0.297-6%
Usd Free Cash Flow To Equity Per Share---0.317-0.3170%-0.007-98%-0.114-64%-0.064-80%-0.053-83%
Usd Market Cap44723948.537+5%42614328.32342614328.3230%44302024.494-4%44442665.842-4%61710610.500-31%91261045.327-53%
Usd Price Per Share1.856+5%1.7691.7690%1.839-4%1.844-4%2.561-31%3.788-53%
Usd Profit---5766956.000-5766956.0000%326685.216-1865%-5441790.350-6%-10906675.451+89%-9517982.173+65%
Usd Revenue----0%-0%-0%-0%3180.698-100%
Usd Total Gains Per Share---0.241-0.2410%0.232-204%-0.013-95%-0.020-92%-0.106-56%
 EOD+6 -2MRQTTM+0 -0YOY+5 -263Y+8 -235Y+12 -1810Y+7 -25

3.3 Fundamental Score

Let's check the fundamental score of Herantis Pharma Oyj based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-7.755
Price to Book Ratio (EOD)Between0-1-157.657
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than12.366
Current Ratio (MRQ)Greater than14.055
Debt to Asset Ratio (MRQ)Less than11.095
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-1.921
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Herantis Pharma Oyj based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose1.600
Total1/1 (100.0%)

4. In-depth Analysis

4.1 About Herantis Pharma Oyj

Herantis Pharma Oyj, a clinical stage biotechnology company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson's disease (PD). The company's lead product in pipeline includes HER-096, an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein that is in phase 1b clinical trial for the treatment of PD and other neurodegenerative diseases. The company was incorporated in 2008 and is based in Espoo, Finland.

Fundamental data was last updated by Penke on 2025-06-30 00:18:06.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its debts by selling its assets.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Herantis earns for each €1 of revenue.

  • Above 10% is considered healthy but always compareΒ Herantis to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 0.0%Β means thatΒ €0.00 for each €1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Herantis Pharma Oyj:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-83,819.4%+83,819.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--90.3%+90.3%
TTM--139.0%+139.0%
YOY--195.4%+195.4%
3Y--247.7%+247.7%
5Y--344.1%+344.1%
10Y-83,819.4%-488.1%-83,331.3%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Herantis is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Herantis to theΒ Biotechnology industry mean.
  • -192.1% Return on Assets means thatΒ Herantis generatedΒ €-1.92 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Herantis Pharma Oyj:

  • The MRQ is -192.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -192.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-192.1%TTM-192.1%0.0%
TTM-192.1%YOY4.1%-196.3%
TTM-192.1%5Y-146.8%-45.3%
5Y-146.8%10Y-104.1%-42.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-192.1%-11.5%-180.6%
TTM-192.1%-11.5%-180.6%
YOY4.1%-11.4%+15.5%
3Y-112.5%-11.7%-100.8%
5Y-146.8%-11.9%-134.9%
10Y-104.1%-13.6%-90.5%
4.3.1.3. Return on Equity

Shows how efficient Herantis is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Herantis to theΒ Biotechnology industry mean.
  • 0.0% Return on Equity means Herantis generated €0.00Β for eachΒ €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Herantis Pharma Oyj:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY5.9%-5.9%
TTM-5Y-873.6%+873.6%
5Y-873.6%10Y-540.2%-333.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--13.6%+13.6%
TTM--14.8%+14.8%
YOY5.9%-14.4%+20.3%
3Y2.0%-16.8%+18.8%
5Y-873.6%-17.5%-856.1%
10Y-540.2%-19.5%-520.7%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Herantis Pharma Oyj.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Herantis is operatingΒ .

  • Measures how much profit Herantis makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Herantis to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated €0.00 Β for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Herantis Pharma Oyj:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-83,355.9%+83,355.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--214.6%+214.6%
TTM--249.7%+249.7%
YOY--208.5%+208.5%
3Y--218.7%+218.7%
5Y--342.8%+342.8%
10Y-83,355.9%-462.5%-82,893.4%
4.3.2.2. Operating Ratio

Measures how efficient Herantis is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are €0.00 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Herantis Pharma Oyj:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y1,420.965-1,420.965
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.093-2.093
TTM-2.680-2.680
YOY-3.076-3.076
3Y-3.518-3.518
5Y-4.734-4.734
10Y1,420.9656.445+1,414.520
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Herantis Pharma Oyj.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Herantis is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 4.06Β means the company has €4.06 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Herantis Pharma Oyj:

  • The MRQ is 4.055. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.055. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.055TTM4.0550.000
TTM4.055YOY3.391+0.664
TTM4.0555Y3.794+0.261
5Y3.79410Y4.254-0.459
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.0553.616+0.439
TTM4.0553.830+0.225
YOY3.3914.140-0.749
3Y3.5744.688-1.114
5Y3.7945.722-1.928
10Y4.2546.144-1.890
4.4.3.2. Quick Ratio

Measures if Herantis is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Herantis to theΒ Biotechnology industry mean.
  • A Quick Ratio of 2.37Β means the company can pay off €2.37 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Herantis Pharma Oyj:

  • The MRQ is 2.366. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.366. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.366TTM2.3660.000
TTM2.366YOY3.757-1.391
TTM2.3665Y3.771-1.406
5Y3.77110Y5.952-2.181
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.3662.826-0.460
TTM2.3663.104-0.738
YOY3.7573.786-0.029
3Y3.2584.311-1.053
5Y3.7715.702-1.931
10Y5.9526.335-0.383
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Herantis Pharma Oyj.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of HerantisΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Herantis to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.09Β means that Herantis assets areΒ financed with 109.5% credit (debt) and the remaining percentage (100% - 109.5%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Herantis Pharma Oyj:

  • The MRQ is 1.095. The company is just not able to pay all its debts by selling its assets. -1
  • The TTM is 1.095. The company is just not able to pay all its debts by selling its assets. -1
Trends
Current periodCompared to+/- 
MRQ1.095TTM1.0950.000
TTM1.095YOY0.299+0.795
TTM1.0955Y0.772+0.322
5Y0.77210Y0.777-0.005
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0950.327+0.768
TTM1.0950.349+0.746
YOY0.2990.332-0.033
3Y0.8010.340+0.461
5Y0.7720.346+0.426
10Y0.7770.378+0.399
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Herantis is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Herantis to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has €0.00 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Herantis Pharma Oyj:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY0.427-0.427
TTM-5Y2.614-2.614
5Y2.61410Y2.671-0.057
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.383-0.383
TTM-0.438-0.438
YOY0.4270.414+0.013
3Y0.1420.450-0.308
5Y2.6140.457+2.157
10Y2.6710.512+2.159
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every €1 in earnings Herantis generates.

  • Above 15 is considered overpriced butΒ always compareΒ Herantis to theΒ Biotechnology industry mean.
  • A PE ratio of -7.39 means the investor is paying €-7.39Β for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Herantis Pharma Oyj:

  • The EOD is -7.755. Based on the earnings, the company is expensive. -2
  • The MRQ is -7.389. Based on the earnings, the company is expensive. -2
  • The TTM is -7.389. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.755MRQ-7.389-0.366
MRQ-7.389TTM-7.3890.000
TTM-7.389YOY135.611-143.000
TTM-7.3895Y21.852-29.241
5Y21.85210Y-1.637+23.489
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.755-2.416-5.339
MRQ-7.389-2.085-5.304
TTM-7.389-2.620-4.769
YOY135.611-3.760+139.371
3Y41.319-3.762+45.081
5Y21.852-6.363+28.215
10Y-1.637-7.055+5.418
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Herantis Pharma Oyj:

  • The EOD is -5.853. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -5.577. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -5.577. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.853MRQ-5.577-0.276
MRQ-5.577TTM-5.5770.000
TTM-5.577YOY-8.186+2.608
TTM-5.5775Y-6.971+1.393
5Y-6.97110Y-17.071+10.100
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-5.853-3.300-2.553
MRQ-5.577-2.737-2.840
TTM-5.577-3.792-1.785
YOY-8.186-4.346-3.840
3Y-6.069-5.095-0.974
5Y-6.971-8.478+1.507
10Y-17.071-9.296-7.775
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Herantis is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of -150.22 means the investor is paying €-150.22Β for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Herantis Pharma Oyj:

  • The EOD is -157.657. Based on the equity, the company is expensive. -2
  • The MRQ is -150.221. Based on the equity, the company is expensive. -2
  • The TTM is -150.221. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-157.657MRQ-150.221-7.437
MRQ-150.221TTM-150.2210.000
TTM-150.221YOY8.029-158.250
TTM-150.2215Y-137.987-12.234
5Y-137.98710Y-192.977+54.991
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-157.6572.119-159.776
MRQ-150.2211.856-152.077
TTM-150.2212.125-152.346
YOY8.0292.439+5.590
3Y-267.2292.485-269.714
5Y-137.9873.667-141.654
10Y-192.9774.337-197.314
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2020-12-312021-12-312022-12-312023-12-312024-12-31
Other Current Assets  17431776424116257-258-1
Net Invested Capital  14,793-8,7336,060442,022448,082-443,3214,761-4,974-213



6.2. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets2,571
Total Liabilities2,814
Total Stockholder Equity-243
 As reported
Total Liabilities 2,814
Total Stockholder Equity+ -243
Total Assets = 2,571

Assets

Total Assets2,571
Total Current Assets2,571
Long-term Assets0
Total Current Assets
Cash And Cash Equivalents 635
Short-term Investments 1,500
Total Current Assets  (as reported)2,571
Total Current Assets  (calculated)2,135
+/- 436
Long-term Assets
Long-term Assets  (as reported)0
Long-term Assets  (calculated)0
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities634
Long-term Liabilities2,180
Total Stockholder Equity-243
Total Current Liabilities
Short Long Term Debt 5
Accounts payable 278
Total Current Liabilities  (as reported)634
Total Current Liabilities  (calculated)283
+/- 351
Long-term Liabilities
Long term Debt 25
Long-term Liabilities Other 2,155
Long-term Liabilities  (as reported)2,180
Long-term Liabilities  (calculated)2,180
+/-0
Total Stockholder Equity
Total Stockholder Equity (as reported)-243
Total Stockholder Equity (calculated)0
+/- 243
Other
Capital Stock80
Common Stock Shares Outstanding 20,161
Net Invested Capital -213
Net Working Capital 1,937



6.3. Balance Sheets Structured

Currency in EUR. All numbers in thousands.

 Trend2024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-31
> Total Assets 
670
2,211
2,641
29,495
14,089
10,205
11,573
7,148
11,071
16,420
6,918
6,232
6,746
2,571
2,5716,7466,2326,91816,42011,0717,14811,57310,20514,08929,4952,6412,211670
   > Total Current Assets 
346
153
43
11,638
5,646
2,895
5,511
2,290
7,260
13,541
6,758
6,232
6,746
2,571
2,5716,7466,2326,75813,5417,2602,2905,5112,8955,64611,63843153346
       Cash And Cash Equivalents 
246
9
18
2,416
541
782
91
719
6,013
12,339
5,630
5,036
5,503
635
6355,5035,0365,63012,3396,013719917825412,416189246
       Short-term Investments 
0
0
0
9,000
5,000
2,047
5,311
1,466
985
985
985
955
985
1,500
1,5009859559859859851,4665,3112,0475,0009,000000
       Net Receivables 
100
144
25
213
87
42
91
94
245
174
118
0
0
0
0001181742459491428721325144100
   > Long-term Assets 
324
2,058
2,598
17,857
8,442
7,311
6,061
4,857
3,811
2,879
160
0
0
0
0001602,8793,8114,8576,0617,3118,44217,8572,5982,058324
       Property Plant Equipment 
4
3
2
2
1
9
7
5
4
0
0
0
0
0
00000457912234
       Goodwill 
0
0
0
905
696
544
311
78
0
0
0
0
0
0
00000078311544696905000
       Long Term Investments 
0
0
0
1
1
1
1
0
0
0
0
0
0
0
00000001111000
       Intangible Assets 
320
2,055
2,596
16,950
7,744
6,757
5,743
4,775
3,807
2,879
160
0
0
0
0001602,8793,8074,7755,7436,7577,74416,9502,5962,055320
       Long-term Assets Other 
0
0
0
1
5,000
2,047
5,311
0
0
0
0
0
0
0
00000005,3112,0475,0001000
> Total Liabilities 
1,920
2,215
2,521
7,774
8,089
8,631
7,482
7,237
9,220
8,833
6,364
6,292
2,019
2,814
2,8142,0196,2926,3648,8339,2207,2377,4828,6318,0897,7742,5212,2151,920
   > Total Current Liabilities 
672
536
670
1,494
578
613
1,460
1,358
2,014
2,892
1,895
1,902
1,989
634
6341,9891,9021,8952,8922,0141,3581,4606135781,494670536672
       Short-term Debt 
0
0
1,850
240
213
103
547
507
6
1,265
222
150
48
0
0481502221,26565075471032132401,85000
       Short Long Term Debt 
0
0
1,850
240
213
103
547
507
6
1,265
912
15,021
5
5
5515,0219121,26565075471032132401,85000
       Accounts payable 
618
468
544
988
189
186
278
200
1,625
716
788
660
749
278
2787496607887161,625200278186189988544468618
       Other Current Liabilities 
55
67
127
267
176
324
634
651
383
911
884
1,091
1,193
0
01,1931,0918849113836516343241762671276755
   > Long-term Liabilities 
1,248
1,679
1,850
6,280
7,512
8,018
6,022
5,878
7,206
5,941
4,469
4,391
30
2,180
2,180304,3914,4695,9417,2065,8786,0228,0187,5126,2801,8501,6791,248
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
5,941
6,288
4,391
0
0
004,3916,2885,941000000000
       Long term Debt 
1,248
1,679
1,850
6,280
7,512
8,018
6,022
5,878
7,206
5,941
6,288
4,391
30
25
25304,3916,2885,9417,2065,8786,0228,0187,5126,2801,8501,6791,248
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
2,155
2,1550000000000000
       Deferred Long Term Liability 
0
0
2,356
16,670
7,518
6,590
5,663
4,735
3,807
2,879
160
0
0
0
0001602,8793,8074,7355,6636,5907,51816,6702,35600
> Total Stockholder Equity
-1,250
-3
120
21,721
5,999
1,575
4,090
-89
1,851
7,587
554
-60
4,726
-243
-2434,726-605547,5871,851-894,0901,5755,99921,721120-3-1,250
   Common Stock
3
3
3
80
80
80
80
80
80
80
80
80
80
0
080808080808080808080333
   Retained Earnings -80,069-75,100-75,380-66,055-54,983-45,830-37,825-33,646-31,481-27,057-11,012-3,427-2,646-2,252
   Capital Surplus 00000000000000
   Treasury Stock00000000000000
   Other Stockholders Equity 
1,000
2,640
0
0
32,976
0
0
0
0
62,490
0
0
0
0
000062,490000032,976002,6401,000



6.4. Balance Sheets

Currency in EUR. All numbers in thousands.




6.5. Cash Flows

Currency in EUR. All numbers in thousands.




6.6. Income Statements

Currency in EUR. All numbers in thousands.


6.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in EUR. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-5,027
Operating Income-5,027-5,027
 
Operating Expense (+$)
Research Development0
Selling General Administrative0
Selling And Marketing Expenses0
Operating Expense5,0270
 
Net Interest Income (+$)
Interest Income52
Interest Expense-6
Other Finance Cost-41
Net Interest Income87
 
Pretax Income (+$)
Operating Income-5,027
Net Interest Income87
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-4,940-5,027
EBIT - interestExpense = -6
-4,940
-4,934
Interest Expense6
Earnings Before Interest and Taxes (EBIT)0-4,934
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-4,940
Tax Provision-0
Net Income From Continuing Ops-4,940-4,940
Net Income-4,940
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0-87
 

Technical Analysis of Herantis
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Herantis. The general trend of Herantis is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Herantis's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Herantis Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Herantis Pharma Oyj.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1.745 < 1.745 < 1.75.

The bearish price targets are: 1.51 > 1.49 > 1.45.

Know someone who trades $HRTIS? Share this with them.πŸ‘‡

Herantis Pharma Oyj Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Herantis Pharma Oyj. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Herantis Pharma Oyj Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Herantis Pharma Oyj.

Herantis Pharma Oyj Daily Moving Average Convergence/Divergence (MACD) ChartHerantis Pharma Oyj Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Herantis Pharma Oyj. The current adx is .

Herantis Pharma Oyj Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Herantis Pharma Oyj.

Herantis Pharma Oyj Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Herantis Pharma Oyj.

Herantis Pharma Oyj Daily Relative Strength Index (RSI) ChartHerantis Pharma Oyj Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Herantis Pharma Oyj.

Herantis Pharma Oyj Daily Stochastic Oscillator ChartHerantis Pharma Oyj Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Herantis Pharma Oyj.

Herantis Pharma Oyj Daily Commodity Channel Index (CCI) ChartHerantis Pharma Oyj Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Herantis Pharma Oyj.

Herantis Pharma Oyj Daily Chande Momentum Oscillator (CMO) ChartHerantis Pharma Oyj Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Herantis Pharma Oyj.

Herantis Pharma Oyj Daily Williams %R ChartHerantis Pharma Oyj Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Herantis Pharma Oyj.

Herantis Pharma Oyj Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Herantis Pharma Oyj.

Herantis Pharma Oyj Daily Average True Range (ATR) ChartHerantis Pharma Oyj Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Herantis Pharma Oyj.

Herantis Pharma Oyj Daily On-Balance Volume (OBV) ChartHerantis Pharma Oyj Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Herantis Pharma Oyj.

Herantis Pharma Oyj Daily Money Flow Index (MFI) ChartHerantis Pharma Oyj Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Herantis Pharma Oyj.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-02-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-28WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-05MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-06RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-17STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-24STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-31STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-04-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-07CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-10SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-04-15STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-04-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-04-29CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-30WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-07WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-13STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-05-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-05-15WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-05-26STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-05-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-02STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-06-03STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-06-04MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-06-05STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-06-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-06-13RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-06-24CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-25STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-30CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-01CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-07BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-07-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-14RSI SHORT ENTRY LONG CLOSE70 crossover to downside

6.3. Candlestick Patterns

Herantis Pharma Oyj Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Herantis Pharma Oyj based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose1.600
Total1/1 (100.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Herantis with someone you think should read this too:
  • Are you bullish or bearish on Herantis? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Herantis? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Herantis Pharma Oyj

I send you an email if I find something interesting about Herantis Pharma Oyj.


Comments

How you think about this?

Leave a comment

Stay informed about Herantis Pharma Oyj.

Receive notifications about Herantis Pharma Oyj in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.